Member Info for daveycaferacer

It's interesting to note that HCM's share price collapse is far worse than any other company on the HFCAA conclusive or provisional list. Most have recovered significantly and are now down single digit %. I guess we also have other headwinds including Shanghai lockdowns, factory inspection delays and a probable subsequent delay in approval of Surufatinib.....

I've never really understood shorting 1pencil, If you opened a short position in the past few weeks or months surely you would now cover and book profits.....

interesting comments from Christian as early as late 2019 on the subject of a forced de-listing:-

"“Nasdaq is a predominant biotech stock exchange, so the prospect of the company delisting there is zero,” Hogg said in an interview late last year with S&P Global."

https://www.fiercepharma.com/special-report/10-biotechs-to-know-china

I have attended from 2012 until they were done remotely. I had intended to attend in HK but will not be doing so and will be attending virtually for a 3rd year in a row.

Our one positive at the moment is sterling is falling and is forecast to fall further as the Fed ratchets up interest rates, promoting a stronger US dollar. the further sterling falls the higher the UK share price gets against the U.S adr

They will have to say something on HFCAA because I will be asking a question ;-))

let's see what management have to say next week on the subject of approvals and also the HFCAA debacle....

The EMA have stated they will do remote/virtual inspections so I'm quite hopeful on approval very soon - we can also expect to see an announcement on a Partner in Europe too.

I expect there to be a number of questions at next week's AGM on the HFCAA and what the Company intends to do about its listings. I hope they are well prepared and we do not get the usual fob-offs. They really need to get their act together on the corporate development side and start having some Beigene style dynamism rather than the pedestrian CKHH style......

thankyou for that 1pencil, very interesting......i assume if the Regulators make some form of positive announcement these would need to be covered fairly quickly....

I have reduced my holding to further diversify but have decided to still retain a 5 digit number of shares

I wonder how General Atlantic feel having paid $30 per adr. How about all the other institutional Investors who have come on board including those who paid $40 hkd.......

7 years of mcap growth wiped out, incredible

My assumption is the Company will get a Star market listing and dump the NASDAQ one, and may well dump the London one too.....

My thought was that the HK listing and subsequent North-South Connect program inclusion together with certain indices inclusion was thought to be very significant, opening investment up to a huge new investment community. Clearly that was short-lived and a potential U.S. de-listing has completely derailed any enthusiasm. Interesting commentary about Charlie Munger there 1Pencil, thanks for posting the video. And given it's tax time in the U.S (I have just filed mine) some investors and even institutions may well have sold HCM at this low price to offset other gains, and could then buy back after the 18th April.

There are things in the piece that are completely applicable, the options around de-listing, taking companies private etc etc and what Companies can do., what options are open to them

https://www.mayerbrown.com/-/media/files/perspectives-events/events/2020/07/how-to-exit-the-us-public-markets-and-options-for-us-listed-chinese-companies.pdf

The Company is now valued approx the same as it was when the pipeline was a fifth of the size and revenues were a third of this years forecast. The market seems to have the view if the company has no U.S. listing it it not worth anything, which I find puzzling. What a disaster.

After many years and many attendance of Board Meetings I cannot sustain the continual, consistent and ever increasing losses so regrettably with a heavy hearth will be selliing my substantial holding. This is a great company but it is very clear that geo-political issues and things far outside the Company's control make the risks too great for most investors. Iam very disappointed because I have invested substantial emotional capital and many hours of research including continual research, getting to know the company, discussions on bulletin boards and many many hours of participation in company presentations since 2006 but the entire exercise has been in vein...... the market and geo-political events have made the company's efforts almost irrelevant. As a person whose wife died of brac2 breast cancer I hope at least that patients benefit even if investors do not.

y It's great but unfortunately the market doesn't care and that is the problem here - the market is completely disconnected with the Company's prospects which is why, for the short to medium term the company is not investible for the ordinary Investor.

EMA "For new sites and facilities within and outside the EEA that have not been inspected or where an inspection is required, a remote inspection may be carried out. On-site inspections will resume as soon as feasible"

So it appears a remote inspection may be sufficient...........we can always hope for some good news, in the meantime I am surprised a partner hasn't been announced yet

The EMA approval is imminent for Surufatinib and we assume this will require a partner so I'm expecting an announcement on that very soon.